FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

AZ promotes a new chief of drug development

John Patterson (photo) is retiring after seeing "mixed" responses from his stint as chief of development at AstraZeneca. Pharmalot notes Patterson, 61, will be replaced by Anders Ekblom, 54, who takes over at the end of January. Ekblom signed on to work at the pharma giant 15 years ago after working at Sweden's prestigious Karolinska Institutet. He is currently head of global clinical development.

Patterson played a key role in the MedImmune acquisition, helping to build AZ's biotech business around the Maryland developer. But he also saw setbacks for some important drug programs for stroke and diabetes.

- check out the AstraZeneca release
- read the report from Pharmalot

Related Articles:
AZ CEO makes new case for drug partnerships
AZ eyes generics, emerging markets
AZ teams up with Singapore cancer centers


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Email Newsletter:

More stories about AstraZeneca   John Patterson   Anders Ekblom